Genomics & Informatics

  • 제16권3호
  • /
  • Pages.52-58
  • /
  • 2018
  • /
  • 1598-866X(pISSN)
  • /
  • 2234-0742(eISSN)
한국유전체학회 (Korea Genome Organization)
권호 표지
DOI QR코드

DOI QR Code

Utility of Integrated Analysis of Pharmacogenomics and Pharmacometabolomics in Early Phase Clinical Trial: A Case Study of a New Molecular Entity

  • Oh, Jaeseong (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) ;
  • Yi, Sojeong (Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration) ;
  • Gu, Namyi (Department of Clinical Pharmacology and Therapeutics, Clinical Trial Center, Dongguk University Ilsan Hospital, Dongguk University College of Medicine) ;
  • Shin, Dongseong (Clinical Trials Center, Gachon University Gil Medical Center) ;
  • Yu, Kyung-Sang (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) ;
  • Yoon, Seo Hyun (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) ;
  • Cho, Joo-Youn (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) ;
  • Jang, In-Jin (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
  • 투고 : 2018.05.08
  • 심사 : 2018.06.11
  • 발행 : 2018.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

In this report, we present a case study of how pharmacogenomics and pharmacometabolomics can be useful to characterize safety and pharmacokinetic profiles in early phase new drug development clinical trials. During conducting a first-in-human trial for a new molecular entity, we were able to determine the mechanism of dichotomized variability in plasma drug concentrations, which appeared closely related to adverse drug reactions (ADRs) through integrated omics analysis. The pharmacogenomics screening was performed from whole blood samples using the Affymetrix DMET (Drug-Metabolizing Enzymes and Transporters) Plus microarray, and confirmation of genetic variants was performed using real-time polymerase chain reaction. Metabolomics profiling was performed from plasma samples using liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. A GSTM1 null polymorphism was identified in pharmacogenomics test and the drug concentrations was higher in GSTM1 null subjects than GSTM1 functional subjects. The apparent drug clearance was 13-fold lower in GSTM1 null subjects than GSTM1 functional subjects (p < 0.001). By metabolomics analysis, we identified that the study drug was metabolized by cysteinylglycine conjugation in GSTM functional subjects but those not in GSTM1 null subjects. The incidence rate and the severity of ADRs were higher in the GSTM1 null subjects than the GSTM1 functional subjects. Through the integrated omics analysis, we could understand the mechanism of inter-individual variability in drug exposure and in adverse response. In conclusion, integrated multi-omics analysis can be useful for elucidating the various characteristics of new drug candidates in early phase clinical trials.

키워드

참고문헌

  1. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012;11:191-200. https://doi.org/10.1038/nrd3681
  2. Merlo-Pich E, Alexander RC, Fava M, Gomeni R. A new population-enrichment strategy to improve efficiency of placebo-controlled clinical trials of antidepressant drugs. Clin Pharmacol Ther 2010;88:634-642. https://doi.org/10.1038/clpt.2010.159
  3. Freidlin B, Korn EL. Biomarker enrichment strategies: matching trial design to biomarker credentials. Nat Rev Clin Oncol 2014;11:81-90. https://doi.org/10.1038/nrclinonc.2013.218
  4. Hollingsworth SJ. Precision medicine in oncology drug development: a pharma perspective. Drug Discov Today 2015;20: 1455-1463. https://doi.org/10.1016/j.drudis.2015.10.005
  5. Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 2004;5:645- 656.
  6. Ahn C. Pharmacogenomics in drug discovery and development. Genomics Inform 2007;5:41-45.
  7. Harper AR, Topol EJ. Pharmacogenomics in clinical practice and drug development. Nat Biotechnol 2012;30:1117-1124. https://doi.org/10.1038/nbt.2424
  8. Liou SY, Stringer F, Hirayama M. The impact of pharmacogenomics research on drug development. Drug Metab Pharmacokinet 2012;27:2-8. https://doi.org/10.2133/dmpk.DMPK-11-RV-093
  9. Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov 2016; 15:473-484. https://doi.org/10.1038/nrd.2016.32
  10. Robertson DG, Frevert U. Metabolomics in drug discovery and development. Clin Pharmacol Ther 2013;94:559-561. https://doi.org/10.1038/clpt.2013.120
  11. Kaddurah-Daouk R, Weinshilboum RM; Pharmacometabolomics Research Network. Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin Pharmacol Ther 2014;95:154-167. https://doi.org/10.1038/clpt.2013.217
  12. Shin KH, Choi MH, Lim KS, Yu KS, Jang IJ, Cho JY. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. Clin Pharmacol Ther 2013;94:601-609. https://doi.org/10.1038/clpt.2013.128
  13. Kim B, Lee J, Shin KH, Lee S, Yu KS, Jang IJ, et al. Identification of omega- or (omega-1)-hydroxylated medium-chain acylcarnitines as novel urinary biomarkers for CYP3A activity. Clin Pharmacol Ther 2018;103:879-887. https://doi.org/10.1002/cpt.856
  14. Yi S, An H, Lee H, Lee S, Ieiri I, Lee Y, et al. Korean, Japanese, and Chinese populations featured similar genes encoding drug-metabolizing enzymes and transporters: a DMET Plus microarray assessment. Pharmacogenet Genomics 2014;24: 477-485. https://doi.org/10.1097/FPC.0000000000000075
  15. Fernandez CA, Smith C, Yang W, Lorier R, Crews KR, Kornegay N, et al. Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther 2012;92:360-365. https://doi.org/10.1038/clpt.2012.95
  16. He YJ, Misher AD, Irvin W Jr, Motsinger-Reif A, McLeod HL, Hoskins JM. Assessing the utility of whole genome amplified DNA as a template for DMET Plus array. Clin Chem Lab Med 2012;50:1329-1334.
  17. Rowbotham MC, Nothaft W, Duan WR, Wang Y, Faltynek C, McGaraughty S, et al. Oral and cutaneous thermosensory pro- file of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial. Pain 2011;152:1192-1200. https://doi.org/10.1016/j.pain.2011.01.051
  18. Quiding H, Jonzon B, Svensson O, Webster L, Reimfelt A, Karin A, et al. TRPV1 antagonistic analgesic effect: a randomized study of AZD1386 in pain after third molar extraction. Pain 2013;154:808-812. https://doi.org/10.1016/j.pain.2013.02.004
  19. Salinas AE, Wong MG. Glutathione S-transferases: a review. Curr Med Chem 1999;6:279-309.
  20. Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet 2012;27:9-54. https://doi.org/10.2133/dmpk.DMPK-11-RV-111
  21. Kasthurinaidu SP, Ramasamy T, Ayyavoo J, Dave DK, Adroja DA. GST M1-T1 null allele frequency patterns in geographically assorted human populations: a phylogenetic approach. PLoS One 2015;10:e0118660. https://doi.org/10.1371/journal.pone.0118660
  22. Fondi M, Lio P. Multi-omics and metabolic modelling pipelines: challenges and tools for systems microbiology. Microbiol Res 2015;171:52-64. https://doi.org/10.1016/j.micres.2015.01.003
  23. Kamoun A, Idbaih A, Dehais C, Elarouci N, Carpentier C, Letouze E, et al. Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas. Nat Commun 2016;7:11263. https://doi.org/10.1038/ncomms11263
  24. Schumacher A, Rujan T, Hoefkens J. A collaborative approach to develop a multi-omics data analytics platform for translational research. Appl Transl Genom 2014;3:105-108. https://doi.org/10.1016/j.atg.2014.09.010